Peter Loftus is a reporter at The Wall Street Journal. He covers a range of topics including pharmaceuticals, medical devices, and healthcare, with a particular focus on pharmaceutical manufacturing, regulation, and wellness programs. Peter's work has been featured in MarketWatch, LiveMint, Yahoo Finance, and MSN, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Peter Loftus' coverage predominantly focuses on the health and healthcare industry, with a specific emphasis on pharmaceutical companies, drug approvals, shortages, leadership changes within these organizations, and medical devices. His articles often cite data or refer to press releases and government announcements.
Given his focus on the pharmaceutical industry and healthcare sector, he is likely to be interested in pitches related to exclusive insights from experts within these industries regarding new drugs (especially weight-loss drugs and diabetes drugs), company strategies for overcoming shortages or handling leadership changes. Furthermore, offering access to credible data or analysis is crucial when pitching potential topics of interest.
Since Peter's geographic focus is not specified but considering that many of the covered companies are based in the US such as Eli Lilly & Co., Johnson & Johnson among others; relevant sources should have knowledge about these companies' operations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Peter Loftus
Surging consumer demand for blockbuster weight loss drugs helped offset declining prices for those drugs.
Peter Loftus Booming sales of weight-loss shots fueled strong revenue and profit growth for Eli Lilly in the latest quarter, as robust consumer demand helped offset falling prices for the drugs.
Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development.
Peter Loftus Eli Lilly Chief Executive Dave Ricks was on stage with Nvidia founder Jensen Huang earlier this year in San Francisco touting
By: Peter Loftus, Nicholas G. Miller
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for drugmaker Pfizer.
By: Peter Loftus
Pfizer Chief Executive Albert Bourla is battling impending expirations for some blockbuster-drug patents and the precipitous decline of the company's Covid franchise, but he has put a date on when the company will return to consistent growth: 2029. Bourla said Tuesday he expects Pfizer will post hi
Scientists have spent years looking for an effective drug to treat hantavirus. - ARGENTINE HEALTH MINISTRY/AFP/Getty Images
Peter Loftus Drug hunters have searched for years for a treatment for the rare infectious disease hantavirus, which caused an outbreak on
By: Peter Loftus
Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares earlier hit $1,149.10, up 6.1%, though the stock has retreated a bit and was recently up 4.2% at $1,128.94. The company’s market capita
